Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

MENA's diabetes action plan to improve the prevention, treatment and care of diabetes

International Diabetes Federation Middle East and North Africa Region (MENA) today launched a diabetes action plan, marking a major step forward towards optimal disease management in type 2 diabetes. The MENA action plan aims to improve the prevention, treatment and care of diabetes, which has reached epidemic proportions in the region and has overtaken wider communicable diseases as a health risk.

8 Oct 2009

FDA approves Daiichi Sankyo's sNDA for Welchol

Daiichi Sankyo, Inc. (DSI) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Welchol® (colesevelam HCl) to be used as an adjunct to diet and exercise for the reduction of elevated low-density lipoprotein cholesterol (LDL-C) in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (heFH) alone or in combination with a statin after failing an adequate trial of diet therapy.

7 Oct 2009

Diabetech and Cinterion Wireless Modules announce their collaboration on fourth generation GlucoMON platform

Cinterion Wireless Modules, the global leader in cellular machine-to-machine (M2M) communication modules, and Diabetech, the leader in patient-centric health care programs, today announced their collaboration on the fourth generation GlucoMON® platform, the world’s easiest-to-use wireless diabetes management system designed to help the over 220 million people worldwide struggling to manage the global diabetes and pre-diabetes pandemic.

7 Oct 2009

Study reveals large structural differences between natural prions and man-made synthetic analogs

A collaboration between scientists at Vanderbilt University and the University of California, San Francisco has led to the first direct information about the molecular structure of prions. In addition, the study has revealed surprisingly large structural differences between natural prions and the closest synthetic analogs that scientists have created in the lab.

7 Oct 2009

Low levels of ROS might protect us from diabetes, says study

We've all heard about the damage that reactive oxygen species (ROS) - aka free radicals - can do to our bodies and the sales pitches for antioxidant vitamins, skin creams or "superfoods" that can stop them. In fact, there is considerable scientific evidence that chronic ROS production within cells can contribute to human diseases, including insulin resistance and type 2 diabetes.

7 Oct 2009

U.S. market for diabetes drugs, devices and monitoring systems to reach over $55 billion by 2016

According to a new report series by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for diabetes drugs, devices and monitoring systems will reach over $55 billion by 2016, tripling in value.

6 Oct 2009

Resveratrol may help improve diet-induced diabetes

Resveratrol, a molecule found in red grapes, has been shown to improve diabetes when delivered orally to rodents. Until now, however, little has been known about how these beneficial changes are mediated in the body.

6 Oct 2009

Fat and muscle mass may contribute to diabetes risk

Fat and muscle mass, as potentially determined by a person's ethnic background, may contribute to diabetes risk, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

6 Oct 2009

Study reveals information about molecular structure of prions

6 Oct 2009

Eat strawberries to improve cholesterol levels

According to a new study published in the October 2009 issue of Nutrition Journal, women with metabolic syndrome had reduced total cholesterol levels - including LDL - after a brief period of daily consumption of a strawberry-based beverage.

6 Oct 2009

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.

5 Oct 2009

VIVUS to present data on Qnexa at The Obesity Society meeting

VIVUS, Inc. today announced that data on Qnexa(TM), an investigational new drug, will be presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley Day, PhD, vice president of clinical development at VIVUS, will present data from the company's two year long phase 3 obesity trials, and Dr. Timothy Garvey, MD, professor of medicine and chair of the department of nutrition sciences at the University of Alabama at Birmingham, will present data from the year long phase 2 study in type 2 diabetics.

5 Oct 2009

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically significant reduction in pain associated with postherpetic neuralgia (PHN) versus placebo using the baseline observation carried forward (BOCF) method required by FDA.

5 Oct 2009

Survey finds majority of Americans are at risk of heart disease due to their lifestyle factor

To help draw attention to National Child Health Day (today), the Preventive Cardiovascular Nurses Association (PCNA) has released findings from a new national consumer survey and launched a campaign to educate families about heart disease, the leading cause of death in the U.S.

5 Oct 2009

Study finds that visual impairment in T1D patients may be decreasing

People diagnosed with type 1 diabetes (T1D) in recent years are less likely to develop diabetes-related vision loss than those diagnosed in earlier years, says a new study funded by the National Eye Institute, a division of the National Institutes of Health. Forecasts of visual impairment prevalence in T1D patients may need to be amended, the researchers suggest, since current predictions assume that the earlier incidence rates will continue.

3 Oct 2009

New study shows that NovoMix 30 is effective for type 2 diabetes patients who are to start on insulin

Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes (EASD) shows that type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix® 30 (biphasic insulin aspart) achieve a significantly greater HbA1c reduction compared to patients starting with a daily injection of insulin glargine.

3 Oct 2009

Self-monitoring of blood glucose helps patients with diabetes to manage their disease better

Self-monitoring of blood glucose (SMBG) enables those with diabetes to modify their behavior, adjust their medicine and understand their disease to better manage it, according to a recent study, published by SAGE in The Diabetes Educator. The research looked at "paired testing," a self-monitored testing both before and after specific events, to evaluate whether it could assist the patient in making better health and food choice decisions over time.

3 Oct 2009

Study finds link between allergic inflammation and nephropathy in men with type 2 diabetes

For men with type 2 diabetes, a cell type linked to allergic inflammation is closely linked to a key indicator of diabetic kidney disease (nephropathy), suggests a study in the November Clinical Journal of the American Society of Nephrology (CJASN). "Allergy is a common disease that is increasing worldwide, so our findings may have important implications for diabetic nephropathy," comments Michiaki Fukui, MD (Kyoto Prefectural University of Medicine, Japan).

3 Oct 2009

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.

3 Oct 2009

Array BioPharma to present poster on ARRY-403 glucokinase activator

Array BioPharma Inc. today announced that a poster on ARRY-403, a novel, oral, glucokinase activator (GKA), will be presented at the European Association for the Study of Diabetes annual meeting, on October 2, 2009, in Vienna, Austria.

2 Oct 2009

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

MENA's diabetes action plan to improve the prevention, treatment and care of diabetes

FDA approves Daiichi Sankyo's sNDA for Welchol

Diabetech and Cinterion Wireless Modules announce their collaboration on fourth generation GlucoMON platform

Study reveals large structural differences between natural prions and man-made synthetic analogs

Low levels of ROS might protect us from diabetes, says study

U.S. market for diabetes drugs, devices and monitoring systems to reach over $55 billion by 2016

Resveratrol may help improve diet-induced diabetes

Fat and muscle mass may contribute to diabetes risk

Study reveals information about molecular structure of prions

Eat strawberries to improve cholesterol levels

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

VIVUS to present data on Qnexa at The Obesity Society meeting

Positive results from Depomed's Phase 3 clinical trial of DM-1796 for postherpetic neuralgia

Survey finds majority of Americans are at risk of heart disease due to their lifestyle factor

Study finds that visual impairment in T1D patients may be decreasing

New study shows that NovoMix 30 is effective for type 2 diabetes patients who are to start on insulin

Self-monitoring of blood glucose helps patients with diabetes to manage their disease better

Study finds link between allergic inflammation and nephropathy in men with type 2 diabetes

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Array BioPharma to present poster on ARRY-403 glucokinase activator

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in